LNS-8801 is under clinical development by Linnaeus Therapeutics and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData, Phase II drugs for Metastatic Uveal Melanoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LNS-8801 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LNS-8801 overview

LNS-8801 is under development for the treatment of solid tumors including melanoma, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, lymphoma, non-small cell lung cancer, mesothelioma, small cell cervical cancer, sarcoma, neuroendocrine cancer, vaginal cancer, nasopharyngeal cancer, uterine cancer, recurrent head and neck squamous cell cancer, cutaneous, colorectal cancer, gastric cancer, metastatic uveal melanoma and stage IIB to stage IV melanoma. The drug candidate acts by targeting G protein-coupled estrogen receptor (GPER). It is administered through oral route.

Linnaeus Therapeutics overview

Linnaeus Therapeutics is a development stage biotech company. It identifies and develops small molecule agents for the treatment of cancer. The company focuses on developing treatments for various cancers, including melanoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer and colon carcinomas. Its lead compound LNS8801 is an agonist of G protein-coupled estrogen receptor (GPER), which has activity across a wide range of preclinical cancer models. Linnaeus Therapeutics is headquartered in Haddonfield, New Jersey, the US

For a complete picture of LNS-8801’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.